This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lesho, E. P.
Right arrow Articles by Moran, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lesho, E. P.
Right arrow Articles by Moran, K. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2006, p. 673, Vol. 44, No. 2
0095-1137/06/$08.00+0     doi:10.1128/JCM.44.2.673.2006

LETTER TO THE EDITOR

De Novo Daptomycin Nonsusceptibility in a Clinical Isolate


arrow
LETTER
 
We report a case of non-daptomycin-susceptible Enterococcus faecium bloodstream infection in a patient with no previous exposure to daptomycin. To our knowledge, this is the first report of de novo resistance to daptomycin in a clinical isolate.

An 84-year-old man was admitted to the hospital because of progressively debilitating weakness and fever. A past medical history of chronic renal insufficiency, compensated congestive heart failure, urinary incontinence, and anemia was elicited. Physical examination findings included a nonradiating systolic heart murmur and mild pitting edema in both lower extremities. There were no skin lesions or rashes and no stigmata of endocarditis. Serum bicarbonate, creatinine, and hematocrit were 19 mmol/liter, 3.2 mg/dl, and 32.5%, respectively. The remainder of his complete blood count and chemistry panel results were normal. Blood cultures were positive for vancomycin-resistant Enterococcus faecium and Enterococcus gallinarum. An echocardiogram revealed echogenic material on the aortic valve consistent with the presence of a vegetation.

Laboratory tests of an E. faecium isolate revealed a MIC for daptomycin as determined by an Epsilometer test (AB Biodisk, Sweden) of 6 µg/ml (a result indicating nonsusceptibility according to the susceptibility breakpoint of ≤4 µg/ml listed in the product package insert). The Epsilometer test was repeated and gave a result of 4 µg/ml. The E. faecium isolate was also resistant to penicillin, ampicillin, gentamicin, and vancomycin but was susceptible to linezolid. The E. gallinarum isolate was susceptible to ampicillin, gentamicin, and vancomycin and was not tested for susceptibility to daptomycin.

Options for treating vancomycin-resistant enterococcal infections remain limited. Promising alternatives include treatment with daptomycin, linezolid, and quinupristin-dalfopristin (for E. faecium only). Daptomycin is considered by many to be an attractive alternative to linezolid and quinupristin-dalfopristin (3, 6). Daptomycin in this patient would have been preferred due to its rapid bactericidal activity, cost considerations, and the absence of the bone marrow suppression that may be seen with linezolid (particularly associated with the longer duration of therapy needed for endocarditis) and because of once-daily dosing. Additionally, compared to linezolid there may be a lesser tendency for the accumulation of potentially harmful metabolites in the setting of renal failure (1).

Based on the recent introduction of daptomycin and the paucity of reports, the development of resistance to this drug in enterococci appears to be rare. Furthermore, spontaneous resistance in an isolate with no preceding exposure to daptomycin has not been previously reported, although there have been four recent reports of emerging daptomycin resistance (3, 4, 5, 7), one involved methicillin-resistant Staphylococcus aureus; all of the cases were associated with prolonged treatment with daptomycin. In a recent review of the world literature on vancomycin-resistant enterococcal endocarditis, (8) there were no instances or reports of daptomycin-resistant native or prosthetic valve endocarditis (8).

A unique aspect of the present case is that the patient had no previous exposure to daptomycin. Additionally, there were no risks known to be associated with the development of multidrug-resistant enterococcal infection, such as longer duration of hospitalization, prolonged stay in an intensive care unit, high APACHE II score, excessive exposure to vancomycin and other antibiotics, repeated abdominal surgeries, and immunosuppression associated with organ transplantation or hematologic malignancy (2, 9). There have been no previous reports of clinical enterococcal isolates initially nonsusceptible to daptomycin at our institution or, to our knowledge, in our community. We are hopeful that this case is not a harbinger of an emerging pattern.


arrow
REFERENCES
 
    1
  1. Anonymous. Linezolid (Zyvox) package insert LAB 0139-10.0, revised May 2005. Pharmacia & Upjohn, Division of Pfizer Inc., New York, N.Y.
    2. 2
  2. Edmond, M. B., J. F. Ober, D. L. Weinbaum, et al. 1995. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin. Infect. Dis. 20:1126-1133.[Medline]
    3. 3
  3. Mangili, A., I. Bica, D. R. Snydman, and D. H. Hamer. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40:1058-1060.[CrossRef][Medline]
    4. 4
  4. Munoz-Price, L. S., K. Lolans, and J. P. Quinn. 2005. Emergence of resistance to daptomycin during treatment of vancomycin resistant Enterococcus faecalis infection. Clin. Infect. Dis. 41:565-566.[CrossRef][Medline]
    5. 5
  5. Sabol, K., J. E. Patterson, J. S. Lewis, A. Owens, J. Cadena, and J. H. Jorgensen. 2005. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. 49:1664-1665.[Free Full Text]
    6. 6
  6. Segreti, J. 11 May 2005, posting date. Efficacy of current agents used in the treatment of gram-positive infections and the consequences of resistance. Clin. Microbiol. Infect. (Suppl. 3):29-35. [Online.]
    7. 7
  7. Silverman, J. A., N. Oliver, T. Andrew, and T. Li. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802.[Abstract/Free Full Text]
    8. 8
  8. Stevens, M. P., and M. B. Edmond. 2005. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin. Infect. Dis. 41:1134-1142.[CrossRef][Medline]
    9. 9
  9. Tonieporth, N. G., R. B. Roberts, J. Joylene, A. Hafner, and L. W. Riley. 1996. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin. Infect. Dis. 23:767-772.[Medline]
Emil P. Lesho*
Glenn W. Wortmann
David Craft
Kimberly A. Moran
Walter Reed Army Medical Center
6900 Georgia Ave., N.W.
Washington, D.C. 20307

* Phone: (202) 782-8722, Fax: (202) 782-3765,, E-mail: Emil.Lesho{at}NA.amedd.army.mil

Journal of Clinical Microbiology, February 2006, p. 673, Vol. 44, No. 2
0095-1137/06/$08.00+0     doi:10.1128/JCM.44.2.673.2006




This article has been cited by other articles:

  • Warren, R. E. (2008). Daptomycin in endocarditis and bacteraemia: a British perspective. J Antimicrob Chemother 62: iii25-iii33 [Abstract] [Full Text]  
  • Hidron, A. I., Schuetz, A. N., Nolte, F. S., Gould, C. V., Osborn, M. K. (2008). Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis. J Antimicrob Chemother 61: 1394-1396 [Full Text]  

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lesho, E. P.
Right arrow Articles by Moran, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lesho, E. P.
Right arrow Articles by Moran, K. A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»